



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 13, 2012

Via E-mail

Mr. Stephen Fellows  
Acting Chief Financial Officer  
Generex Biotechnology Corporation  
33 Harbour Square, Suite 202  
Toronto, Canada M5J 2G2

**Re: Generex Biotechnology Corporation  
Form 10-K for the Fiscal Year Ended July 31, 2011  
Filed October 14, 2011  
File No. 000-25169**

Dear Mr. Fellows:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Gus Rodriguez

Gus Rodriguez

Accounting Branch Chief